Calcineurin inhibitor-free immunosuppression after heart transplantation: Can chronic side effects be avoided?

Current Opinion in Organ Transplantation

Volumn 10, Issue 4, 2005, Pages 360-363

  Groetzner, Jan ^a   Wahlers, Thorsten ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Calcineurin inhibitors; Heart transplantation; Mycophenolate mofetil; Rapamycin; Side effects

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID;

CARDIAC GRAFT REJECTION; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE EXACERBATION; FOLLOW UP; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; PNEUMONIA; REVIEW;

EID: 28044456057     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/01.mot.0000186947.23438.3e     Document Type: Review

References (22)

1. Trulock EP, Edwards LB, Taylor DO, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-first official adult heart transplant report - 2004. J Heart Lung Transplant 2004; 23:804-815.
2. Reichart B, Meiser B, Vigano M, et al. European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results - European Tacrolimus Multicenter Heart Study Group. J Heart Lung Transplant 1998; 17:775-781.
3. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931-940.
4. Van Gelder T, Balk AH, Zietse R. Renal insufficiency after heart transplantation: a case control study. Nephrol Dial Transplant 1998; 13:2322-2326.
5. Meiser BM, Groetzner J, Kaczmarek I, et al. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? Transplantation 2004; 78:591-598.
6. Aleksic I, Baryalei M, Busch T, et al. Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine. Transplantation 2000; 69:1586-1590.
7. Angermann CE, Stork S, Costard-Jackle A, et al. Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients - the IMPROVED multi-centre study. Eur Heart J 2004; 25:1626-1634. A well-designed multicenter trial in heart transplant recipients with chronic renal failure comparing routine calcineurin inhibitor-based immunosuppression with calcineurin inhibitor-reduced immunosuppression (plus mycophenolate mofetil).
8. Schlitt HJ, Barkmann A, Schmidt HJ, et al. Replacement of calcineurin inhibitors with MMF in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001; 357:587-591.
9. Groetzner J, Schirmer J, Kaczmarek J, et al. Complete immunosuppressive conversion from calcineurin-inhibitors to mycophenolate mofetil and steroids in cardiac transplant recipients with chronic renal failure. Thorac Cardiovasc Surg 2004; 52.
10. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369:756-758.
11. Sehgal SN. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995; 17:660-665.
12. Mueller M, Meiser B, Groetzner J, et al. The combination of sirolimus and tacrolimus for primary immunosuppression after heart transplantation-is it worth the effort. J Heart Lung Transplant 2005; 24(Suppl 2):S63.
13. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004; 110:2694-2700. This is the first large, randomized study to report the effects of sirolimus in heart transplant recipients (rejection, graft vessel disease, malignancies).
14. Eisen HJ, Tuzcu EM, Dorent R, et al. RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349:847-858.
15. Snell GI, Levvey BJ, Chin W, et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002; 21:540-546.
16. Trösch F, Rothenburger M, Schneider M, et al. First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation. Thorac Cardiovasc Surg 2004; 52:163-168.
17. Lyster H, Panicker G, Leaver N, Banner NR. Initial experience with sirolimus and mycophenolate mofetil for renal rescue from cyclosporine nephrotoxicity after heart transplantation. Transplant Proc 2004; 36:3167-3170.
18. Hunt J, Lerman M, Magee MJ, Dewey TM, Herbert M, Mack MJ. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation. J Heart Lung Transplant - 23:113S. 2004.
19. Hariri K, Roedler S, Dunkler D, et al. Sirolimus (srl) and its effects after 12 month therapy on patients with calzineurin (cni) induced renal dysfunction. J Heart Lung Transplant Feb 2005; (Vol 24, Issue 2) (Supplement), pages S151-S152).
20. Groetzner J, Meiser B, Landwehr P, et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for cardiac transplant recipients with chronic renal failure. Transplantation 2004; 77:568-574. This paper reports on first data from a prospective conversion study to a calcineurin inhibitor-free regimen (mycophenolate mofetil and sirolimus) after heart transplantation.
21. Meiser B, Reichart B, Adamidis I, et al. First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation. Am J Transplant 2005; 5:827-831. The first innovative report of calcineurin inhibitor-fee immunosuppression in 8 de-novo heart transplant recipients.
22. Kaplinsky EJ, Manito N, Roca J, et al. Sirolimus in heart transplantation: a single center initial experience. Transplant Proc 2003; 35:1978-1980.